Segment Reporting - Schedule of Segment Reporting Information, by Segment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Segment Reporting Information [Line Items]
Segment revenue	$ (29)	$ 3,032
Research and development
Selling, general and administrative	23,339	23,944
Restructuring, long-lived assets impairment and related charges, net	0	(10)
Net loss	(125,695)	(120,965)
Reportable Segment
Segment Reporting Information [Line Items]
Segment revenue	(29)	3,032
Research and development
Contract manufacturing	36,007	9,336
Personnel	31,528	33,718
Clinical costs	26,134	20,606
Licenses, collaborations and contingent consideration, net	(2,809)	36,591
Other R&D	18,062	18,394
Selling, general and administrative	23,339	23,944
Restructuring, long-lived assets impairment and related charges, net	0	(10)
Plus: Other segment items	6,595	18,582
Net loss	$ (125,695)	$ (120,965)